Early Access

10-Q/APeriod: Q2 FY2011

VERTEX PHARMACEUTICALS INC / MA Quarterly Report (Amendment) for Q2 Ended Jun 30, 2011

Filed March 2, 2012For Securities:VRTX

Summary

This filing is an amendment (No. 2) to Vertex Pharmaceuticals Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2011. The primary purpose of this amendment is to refile certain exhibits with fewer redactions, specifically related to agreements. It's important to note that this amendment does not update the financial or operational disclosures beyond the original filing date of August 9, 2011, and continues to speak as of that date. Investors should recognize that the core financial and business information presented in this report reflects the company's status as of mid-2011. The focus of the amendment is on the disclosure of contractual arrangements, particularly highlighting a License and Collaboration Agreement with Alios BioPharma, Inc. dated June 13, 2011, and various amendments to its significant Research, Development, and Commercialization Agreement with the Cystic Fibrosis Foundation Therapeutics Incorporated.

Key Highlights

  • 1This is an amendment (No. 2) to the 10-Q for the quarter ended June 30, 2011, filed on August 9, 2011. The amendment's main purpose is to file certain exhibits with reduced redactions and include new officer certifications.
  • 2The amendment refiles Exhibit 10.1, a License and Collaboration Agreement between Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc., dated June 13, 2011.
  • 3The filing includes an updated Exhibit Index and officer certifications in accordance with Rule 13a-14(a) of the Exchange Act.
  • 4Vertex Pharmaceuticals was classified as a 'Large accelerated filer' as of July 29, 2011, with approximately 208,087,899 shares of common stock outstanding.
  • 5The report confirms Vertex is not a shell company and has been subject to the filing requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 for the preceding 12 months.
  • 6Several agreements with the Cystic Fibrosis Foundation Therapeutics Incorporated are listed, including the original Research, Development and Commercialization Agreement dated May 24, 2004, and various amendments.

Frequently Asked Questions